Amgen/$AMGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Ticker
$AMGN
Sector
Primary listing
Employees
28,000
Headquarters
Website
Amgen Metrics
BasicAdvanced
$159B
24.09
$12.23
0.48
$9.39
3.23%
Price and volume
Market cap
$159B
Beta
0.48
52-week high
$335.88
52-week low
$253.30
Average daily volume
2.6M
Dividend rate
$9.39
Financial strength
Current ratio
1.306
Quick ratio
0.817
Long term debt to equity
723.748
Total debt to equity
756.651
Dividend payout ratio (TTM)
73.00%
Interest coverage (TTM)
3.11%
Profitability
EBITDA (TTM)
16,148
Gross margin (TTM)
71.36%
Net profit margin (TTM)
18.96%
Operating margin (TTM)
32.27%
Effective tax rate (TTM)
10.84%
Revenue per employee (TTM)
$1,250,000
Management effectiveness
Return on assets (TTM)
7.88%
Return on equity (TTM)
99.14%
Valuation
Price to earnings (TTM)
24.09
Price to revenue (TTM)
4.535
Price to book
21.35
Price to tangible book (TTM)
-4.42
Price to free cash flow (TTM)
14.932
Free cash flow yield (TTM)
6.70%
Free cash flow per share (TTM)
19.73
Dividend yield (TTM)
3.19%
Forward dividend yield
3.23%
Growth
Revenue change (TTM)
12.88%
Earnings per share change (TTM)
110.32%
3-year revenue growth (CAGR)
9.79%
10-year revenue growth (CAGR)
5.33%
3-year earnings per share growth (CAGR)
1.15%
10-year earnings per share growth (CAGR)
4.94%
3-year dividend per share growth (CAGR)
7.76%
10-year dividend per share growth (CAGR)
12.71%
What the Analysts think about Amgen
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Bulls say / Bears say
Amgen reported Q2 2025 revenues of $9.2 billion, up 9% year-over-year, and adjusted EPS of $6.02, both surpassing analyst forecasts and reflecting broad-based volume growth across 15 key products (Reuters).
The company raised its full-year 2025 guidance to $20.20–$21.30 in adjusted EPS and $35–$36 billion in revenues, signaling strong confidence in its growth trajectory and pipeline momentum (Reuters).
Amgen’s experimental weight-loss drug MariTide delivered promising mid-stage results with pivotal data expected in Q4 2025, diversifying its pipeline beyond traditional therapeutic areas and offering a potential blockbuster opportunity (Reuters).
Prolia sales declined 4% year-over-year to $1.1 billion in Q2 2025 due to rising biosimilar competition, pointing to erosion in one of Amgen’s core franchises (Reuters).
Swiss generics firm Sandoz filed a U.S. antitrust lawsuit in April 2025 alleging Amgen unlawfully blocked biosimilar competition for its arthritis drug Enbrel—Enbrel generated $3.3 billion in U.S. sales in 2024—highlighting regulatory and legal challenges to that franchise (Reuters).
Amgen warned that U.S. government drug-pricing reforms and potential European Union import tariffs could constrain pricing flexibility and margin growth, representing a headwind to revenue expansion (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Amgen Financial Performance
Revenues and expenses
Amgen Earnings Performance
Company profitability
Amgen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amgen stock?
Amgen (AMGN) has a market cap of $159B as of October 10, 2025.
What is the P/E ratio for Amgen stock?
The price to earnings (P/E) ratio for Amgen (AMGN) stock is 24.09 as of October 10, 2025.
Does Amgen stock pay dividends?
Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of October 10, 2025, the dividend rate is $9.39 and the yield is 3.23%. Amgen has a payout ratio of 73% on a trailing twelve-month basis.
When is the next Amgen dividend payment date?
The next Amgen (AMGN) dividend payment date is unconfirmed.
What is the beta indicator for Amgen?
Amgen (AMGN) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.